» Articles » PMID: 20534970

Vertebral Fractures in Dialysis: Endocrinological Disruption of the Bone-kidney Axis

Overview
Publisher Springer
Specialty Endocrinology
Date 2010 Jun 11
PMID 20534970
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The occurrence of metabolic bone disease in patients with renal dysfunction is due to the key role played by the kidney in regulating calcium-phosphate metabolism. The incidence of hip fractures in end-stage renal disease is 3- to 4-fold higher than the general population, while poor data about vertebral fractures show similar prevalence. Bone health has been mainly evaluated in the general population through bone mass density (BMD) measurements, while in Chronic Kidney Disease (CKD) patients, bone turnover (low or high turnover) has been considered the most relevant parameter. Indeed, in CKD patients, the association between BMD and fractures is unclear, and even studies on established risk factors (body mass index, PTH, and vitamin D) for fractures have contrasting outcomes. Recently, an important association has been found between bone disorders and vascular calcifications in CKD patients that has changed the denomination of renal osteodystrophy in CKD mineral and bone disorder. In this article, a poorly investigated subject, vertebral fractures in CKD patients, is addressed, as it is underestimated despite its remarkable clinical relevance.

Citing Articles

Vertebral fractures in patients with CKD and the general population: a call for diagnosis and action.

Gifre L, Masso E, Fusaro M, Haarhaus M, Urena P, Cozzolino M Clin Kidney J. 2024; 17(8):sfae191.

PMID: 39099567 PMC: 11294886. DOI: 10.1093/ckj/sfae191.


Micropetrosis in hemodialysis patients.

Yajima A, Tsuchiya K, Burr D, Murata T, Nakamura M, Inaba M Bone Rep. 2021; 15:101150.

PMID: 34926729 PMC: 8649646. DOI: 10.1016/j.bonr.2021.101150.


Prevalence of Vertebral Fractures and Their Prognostic Significance in the Survival in Patients with Chronic Kidney Disease Stages 3‒5 Not on Dialysis.

Castro-Alonso C, DMarco L, Pomes J, Del Amo Conill M, Garcia-Diez A, Molina P J Clin Med. 2020; 9(5).

PMID: 32466297 PMC: 7291319. DOI: 10.3390/jcm9051604.


Uremic osteoporosis.

Kazama J, Iwasaki Y, Fukagawa M Kidney Int Suppl (2011). 2014; 3(5):446-450.

PMID: 25019028 PMC: 4089591. DOI: 10.1038/kisup.2013.93.


Significant effect of raloxifene on bone in hemodialysis patients.

Ravn P Int J Endocrinol Metab. 2013; 10(4):636-7.

PMID: 23843837 PMC: 3693645. DOI: 10.5812/ijem.6251.


References
1.
Guglielmi G, Andreula C, Muto M, Gilula L . Percutaneous vertebroplasty: indications, contraindications, technique, and complications. Acta Radiol. 2005; 46(3):256-68. DOI: 10.1080/02841850510021049. View

2.
Bergner R, Henrich D, Hoffmann M, Schmidt-Gayk H, Lenz T, Upperkamp M . Treatment of reduced bone density with ibandronate in dialysis patients. J Nephrol. 2008; 21(4):510-6. View

3.
Genant H, Wu C, van Kuijk C, Nevitt M . Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8(9):1137-48. DOI: 10.1002/jbmr.5650080915. View

4.
Rico H, Aguado F, Revilla M, Villa L, Martin J . Ultrasound bone velocity and metacarpal radiogrametry in hemodialyzed patients. Miner Electrolyte Metab. 1994; 20(3):103-6. View

5.
Pluskiewicz W, Adamczyk P, Drozdzowska B, Szprynger K, Szczepanska M, Halaba Z . Skeletal status in children, adolescents and young adults with end-stage renal failure treated with hemo- or peritoneal dialysis. Osteoporos Int. 2002; 13(5):353-7. DOI: 10.1007/s001980200039. View